文献速递睡眠呼吸障碍

德国多中心上市后研究:上气道刺激治疗OSA一年结局

Outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter German post-market study.
PubMed 文献 · Laryngoscope · 2017-05-31

该多中心前瞻性单臂研究纳入60例接受舌下神经上气道刺激(UAS)的中重度阻塞性睡眠呼吸暂停(OSA)患者,在德国三个中心随访12个月。中位呼吸暂停低通气指数(AHI)从基线28.6降至12个月时的9.5,Epworth嗜睡量表(ESS)和睡眠功能结局问卷(FOSQ)均较基线显著改善。平均使用时间为每周39.1±14.9小时。研究认为UAS在常规临床实践中是安全有效的治疗选择。

要点

  • 中位AHI从基线28.6降至12个月时的9.5。
  • ESS与FOSQ从基线至12个月均显著改善。
  • 植入设备记录的平均使用时间为每周39.1±14.9小时。

核心结论

  • UAS是常规临床实践中OSA患者安全有效的治疗选择。
  • 12个月随访显示客观指标与患者报告结局均改善。

研究设计与样本

  • 多中心前瞻性单臂研究,纳入德国三个中心连续接受UAS系统(Inspire Medical Systems)的患者。
  • 共60例参与者,关键排除标准包括BMI>35 kg/m2、AHI<15或>65、以及镇静内镜下软腭完全同心圆塌陷。
  • 在6个月和12个月访视时收集家庭睡眠检测和患者报告结局指标。
  • 证据等级为4。

主要发现

  • 中位AHI从基线28.6降至12个月时的9.5。
  • ESS和FOSQ从基线至12个月均显著改善。
  • 基于植入设备记录,所有参与者平均使用时间为每周39.1±14.9小时。
  • 1例患者因外观及其他个人原因要求移除设备,移除完成且无后遗症。

关键数值与推荐

  • 关键排除标准:BMI>35 kg/m2、AHI<15或>65、镇静内镜下软腭完全同心圆塌陷。

临床怎么用

  • UAS可作为不能耐受持续气道正压通气(CPAP)的中重度OSA患者的治疗选择。
  • 植入后12个月随访可见AHI、ESS和FOSQ改善。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/HYPOTHESIS: Upper airway stimulation (UAS) of the hypoglossal nerve has been implemented in the routine clinical practice for patients with moderate-to-severe obstructive sleep apnea (OSA) who could not adhere to continuous positive airway pressure. This study reports objective and patient-reported outcome after 12 months of implantation. STUDY DESIGN: Multicenter prospective single-arm study. METHODS: Consecutive patients who received the UAS system (Inspire Medical Systems, Inc., Minneapolis, Minnesota, Maple Grove, MN, U.S.A.) were enrolled in three German centers. Key study exclusion criteria included body mass index > 35 kg/m2 , apnea-hypopnea index (AHI) < 15 or > 65, or complete concentric collapse at the soft palate during sedated endoscopy. Data collection at 6- and 12-month visit include home sleep test and patient-reported outcome measures. RESULTS: Among the total of 60 participants, the median AHI reduced from 28.6 to 9.5 from baseline to 12 months. Patient-reported outcome measured in Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire both improved significantly from baseline to 12 months. The average usage time was 39.1 ± 14.9 hours per week among all participants based on recordings by the implanted device. One patient requested a removal of the device for cosmetic and other personal reasons and was completed without sequelae. CONCLUSION: This study supported that UAS is a safe and effective treatment option for patients with OSA in routine clinical practice. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:509-515, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Steffen A, Sommer JU, Hofauer B, et al. Outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter German post-market study. Laryngoscope. 2017. PMID: 28561345. doi:10.1002/lary.26688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。